Marina Says Initial Tox Data Shows FAP Drug to be Safe
October 28, 2010
Marina Says Initial Tox Data Shows FAP Drug to be Safe
CEQ508 is based on Cequent Pharmaceuticals' so-called transkingdom RNAi technology, and is designed to inhibit the oncogene beta-catenin, which is expected to prevent new polyp formation associated with the disease.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- As Big Pharma Looks to Niche Diseases, RNAi May Benefit
May 30, 2013 / Gene Silencing News - Marina Reacquires Agricultural, Veterinary Rights to RNAi Tech
April 19, 2012 / Gene Silencing News - Marina Preps for Additional Patient Enrollment in FAP Trial, Predicts Pharma Partnership This Year
January 26, 2012 / Gene Silencing News - Marina Completes Enrollment of First Cohort in FAP Drug Trial
April 21, 2011 / Gene Silencing News - Marina Biotech Advances FAP Drug into Phase I
March 17, 2011 / Gene Silencing News